Colon cancer breakthrough keeps patients cancer-free for nearly 3 years
A short burst of immunotherapy before surgery is delivering surprisingly powerful results for a specific type of colorectal cancer. Patients in a UK-led trial who received just nine weeks of pembrolizumab prior to surgery have remained cancer-free nearly three years later—an outcome that challenges the standard approach of surgery followed by months of chemotherapy.
